{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-000776","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.029203+00:00","generated_at":"2026-06-07T02:45:27.843886+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioLife Q4 preliminary revenue $32.7M, down 26% YoY; cell processing up 11% sequentially","bullets":["Q4 2023 total preliminary unaudited revenue $32.7M, down 26% vs Q4 2022 ($44.3M).","Cell processing platform revenue $14.8M, down 27% YoY but up 11% sequentially from Q3 2023.","Full-year 2023 revenue $143.3M, down 11% from $161.8M in 2022.","Divestiture of freezer business progressing; expected to close in Q1 2024.","CEO cites 14 approved CGT therapies using BioLife products; 10 more potential by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-000776","json":"https://secwatch.observer/filing/0001628280-24-000776.json","markdown":"https://secwatch.observer/filing/0001628280-24-000776.md","text":"https://secwatch.observer/filing/0001628280-24-000776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/blfs-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:45:27.843886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e33e3064429f46092fac377d8a9a98b3debb9c8","claim":"BIOLIFE SOLUTIONS INC reported the fourth quarter of 2023 results: revenue $32.7 million.","evidence_excerpt":"Preliminary and unaudited revenue for the fourth quarter of 2023 was $32.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2023"},{"label":"Revenue","value":"$32.7 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"f9d864de99aef232d3a4b5fd26a4ce24b89039ec","claim":"BIOLIFE SOLUTIONS INC reported the full year 2023 results: revenue $143.3 million.","evidence_excerpt":"Preliminary and unaudited revenue for the full year 2023 was $143.3 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828024000776/0001628280-24-000776-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year 2023"},{"label":"Revenue","value":"$143.3 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}